Dr Marco Gerlinger studied Medicine in Munich, Wurzburg, London and Boston. After obtaining his MD from the Institute for Immunology in Munich, he undertook postdoctoral training in cancer immunotherapy at the University of Zurich. He specialized in Internal Medicine and Medical Oncology in Zurich and London.
As a postdoc and subsequently as a clinician scientist at the Cancer Research UK London Research Institute, he investigated biomarkers of targeted cancer drug resistance and developed technologies to measure and track genetic and functional intra tumour heterogeneity and cancer evolution.
Dr Gerlinger joined the ICR's Centre for Evolution and Cancer as a team leader in October 2013. He was also a Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust where he treated patients with gastrointestinal cancers.
Dr Gerlinger left the ICR in January 2022.